GlassScriptPhysician profile
Eric O Gyuricsko
NPI 1215987854
$7,647.37
in general payments reported to CMS, 2019-2025
24 companies · $4,114 in 2025
The $4,114 reported for 2025 was more than what 82% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2021: $115 · 2022: $220 · 2023: $553 · 2024: $2,440 · 2025: $4,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,600 · Travel and Lodging: $1,857 · Food and Beverage: $1,626 · Education: $23.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,600.00 |
| Travel and Lodging | $1,856.86 |
| Food and Beverage | $1,626.18 |
| Education | $23.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $5,875.79 | 2023-2025 | |
| Arbor Pharmaceuticals, INC. | $205.77 | 2019 | |
| Medtronic, INC. | $185.77 | 2023-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Biomarin Pharmaceutical INC. | $180.40 | 2022-2024 | Voxzogo 1.2mg |
| Novo Nordisk INC | $169.62 | 2023-2025 | Sogroya |
| Ascendis Pharma Endocrinology INC | $164.94 | 2022-2025 | Yorvipath |
| Xeris Pharmaceuticals, INC. | $132.48 | 2021-2025 | Gvoke Hypopen |
| Kyowa Kirin, INC. | $122.73 | 2023-2025 | Crysvita |
| Abbvie INC. | $99.74 | 2023-2025 | |
| Neurelis, INC. | $93.44 | 2023 | Valtoco |
| Sandoz INC. | $56.66 | 2025 | Omnitrope |
| Azurity Pharmaceuticals, INC. | $53.48 | 2024-2025 | Triptodur |
| Dexcom, INC. | $52.88 | 2023 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $38.70 | 2025 | |
| Beta Bionics, INC. | $35.41 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $34.06 | 2023-2024 | Omnipod |
| Abbott Laboratories | $33.70 | 2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $23.49 | 2025 | |
| Endo Pharmaceuticals INC. | $21.87 | 2023 | Supprelin |
| Soleno Therapeutics, INC. | $18.52 | 2025 | Vykat Xr |
| Sequel Med Tech, LLC | $17.59 | 2025 | Twiist |
| Endo USA, INC. | $16.31 | 2024 | Supprelin |
| Amphastar Pharmaceuticals, INC. | $14.02 | 2024 | Baqsimi |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Gyuricsko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.